Treosulfan Pharmacokinetics in AML/MDS Patients Undergoing AlloHSCT

Phase 1, open-label, single-arm trial of treosulfan in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by medac GmbH. Primary endpoints: Area Under the Concentration-time Curve From Time of Administration to the Last Measurable Concentration for Treosulfan and Area Under the Concentration-time Curve From Time of Administration to Time of Infinity for Treosulfan. Started Feb 2024; status: completed.